These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2635 related items for PubMed ID: 33508920

  • 1. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD, Zhang H, Dong L, Jiang KW, Ye YJ, Wang S, Zhou J.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb 25; 24(2):145-152. PubMed ID: 33508920
    [Abstract] [Full Text] [Related]

  • 2. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW, Zang L, Ma JJ, Sun J, Yang X, Wang ML, Lu AG, Hu WG, Zheng MH.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb 25; 24(2):138-144. PubMed ID: 33508919
    [Abstract] [Full Text] [Related]

  • 3. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
    Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, Yu J, Bu Z, Chen L, Du Y, Wang X, Wu A, Li G, Su X, Xiao G, Cui M, Wu D, Chen L, Wu X, Zhou Y, Zhang L, Dang C, He Y, Zhang Z, Sun Y, Li Y, Chen H, Bai Y, Qi C, Yu P, Zhu G, Suo J, Jia B, Li L, Huang C, Li F, Ye Y, Xu H, Wang X, Yuan Y, E JY, Ying X, Yao C, Shen L, Ji J, RESOLVE study group.
    Lancet Oncol; 2021 Aug 25; 22(8):1081-1092. PubMed ID: 34252374
    [Abstract] [Full Text] [Related]

  • 4. [Postoperative complications and their influence on the prognosis factors in gastric cancer patients receiving neoadjuvant treatment].
    Wang TB, Mao QK, Zhang XJ, Zhou H, Guo CG, Chen YT, Zhao DB.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb 25; 24(2):160-166. PubMed ID: 33508922
    [Abstract] [Full Text] [Related]

  • 5. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
    Wang X, Li S, Sun Y, Li K, Shen X, Xue Y, Liang P, Li G, Chen L, Zhao Q, Li G, Fu W, Liang H, Xin H, Suo J, Fang X, Zheng Z, Xu Z, Chen H, Zhou Y, He Y, Huang H, Zhu L, Yang K, Ji J, Ye Y, Zhang Z, Li F, Wang X, Tian Y, Park S, Chen L.
    BMC Cancer; 2021 Jan 05; 21(1):20. PubMed ID: 33402102
    [Abstract] [Full Text] [Related]

  • 6. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
    Peng L, Yang W, Zhang Z, Zhi C, Zhou X, Liu H, Hua Y.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct 25; 21(10):1148-1153. PubMed ID: 30370514
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
    Shin K, Park SJ, Lee J, Park CH, Song KY, Lee HH, Seo HS, Jung YJ, Park JM, Lee SH, Roh SY, Kim IH.
    BMC Cancer; 2019 Dec 18; 19(1):1232. PubMed ID: 31852475
    [Abstract] [Full Text] [Related]

  • 8. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y, Wang Q, Wang J, Qiao XY, Zhang J, Lin YC, Li Y, Fan LQ, Yang PG, Zhao Q.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb 25; 24(2):128-137. PubMed ID: 33508918
    [Abstract] [Full Text] [Related]

  • 9. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
    Jiang Z, Sun Y, Zhang W, Cui C, Yang L, Zhou A.
    Asia Pac J Clin Oncol; 2020 Jun 25; 16(3):180-186. PubMed ID: 32077628
    [Abstract] [Full Text] [Related]

  • 10. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
    Ding XW, Zheng ZC, Zhao Q, Zhai G, Liang H, Wu X, Zhu ZG, Wang HJ, He QS, He XL, Du YA, Chen LC, Hua YW, Huang CM, Xue YW, Zhou Y, Zhou YB, Wu D, Fang XD, Dai YG, Zhang HW, Cao JQ, Li LP, Chai J, Tao KX, Li GL, Jie ZG, Ge J, Xu ZF, Zhang WB, Li QY, Zhao P, Ma ZQ, Yan ZL, Zheng GL, Yan Y, Tang XL, Zhou X.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May 25; 24(5):403-412. PubMed ID: 34000769
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study.
    Chen L, Zhang C, Yao Z, Cui M, Xing J, Yang H, Zhang N, Liu M, Xu K, Tan F, Li Y, Jiang B, Su X.
    BMC Cancer; 2021 Aug 30; 21(1):974. PubMed ID: 34461860
    [Abstract] [Full Text] [Related]

  • 12. [Clinical value of superior mesenteric vein (No.14v) lymph node dissection in D2 gastrectomy for locally advanced distal gastric cancer].
    Lu W, Zeng X, Li N, Liu H.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct 25; 21(10):1136-1141. PubMed ID: 30370512
    [Abstract] [Full Text] [Related]

  • 13. Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy.
    Feng D, Leong M, Li T, Chen L, Li T.
    World J Surg Oncol; 2015 Jan 30; 13():11. PubMed ID: 25634099
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
    Shitara K, Chin K, Yoshikawa T, Katai H, Terashima M, Ito S, Hirao M, Yoshida K, Oki E, Sasako M, Emi Y, Tsujinaka T.
    Gastric Cancer; 2017 Jan 30; 20(1):175-181. PubMed ID: 26626800
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
    Cheng X, Wu D, Xu N, Chen L, Yan Z, Chen P, Zhou L, Yu J, Cui J, Li W, Wang C, Feng W, Wei Y, Yu P, Du Y, Ying J, Xu Z, Yang L, Zhang Y.
    BMC Cancer; 2021 Jan 12; 21(1):56. PubMed ID: 33435909
    [Abstract] [Full Text] [Related]

  • 16. Comparison of Long-Term Efficacy in S-1 and Capecitabine With Oxaliplatin as Adjuvant Chemotherapy for Patients With Gastric Cancer After Curative Surgery: A Retrospective, Single-Center Observational Study.
    Oh SE, An JY, Choi MG, Lee JH, Sohn TS, Bae JM.
    Technol Cancer Res Treat; 2021 Jan 12; 20():15330338211039679. PubMed ID: 34605706
    [Abstract] [Full Text] [Related]

  • 17. Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification.
    Wei J, Yao T, Wang Y, Li L, Pan C, Zhang N.
    Clin Transl Oncol; 2019 Feb 12; 21(2):232-238. PubMed ID: 29968135
    [Abstract] [Full Text] [Related]

  • 18. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.
    Nakamura Y, Yamanaka T, Chin K, Cho H, Katai H, Terashima M, Misawa K, Hirao M, Yoshida K, Oki E, Sasako M, Emi Y, Bando H, Kawashima Y, Fukunaga T, Gotoh M, Ishibashi T, Shitara K.
    Ann Surg Oncol; 2019 Feb 12; 26(2):465-472. PubMed ID: 30456678
    [Abstract] [Full Text] [Related]

  • 19. A two centers study of postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX regimens for gastric cancer after D2 resection: a cohort study.
    Zheng S, Zhou Y, Sun Y, Wang Z, Lu Y.
    Cancer Chemother Pharmacol; 2019 Oct 12; 84(4):819-827. PubMed ID: 31388724
    [Abstract] [Full Text] [Related]

  • 20. Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinoma.
    Honma Y, Yamada Y, Terazawa T, Takashima A, Iwasa S, Kato K, Hamaguchi T, Shimada Y, Ohashi M, Morita S, Fukagawa T, Machida N, Katai H.
    Surg Today; 2016 Sep 12; 46(9):1076-82. PubMed ID: 26563224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 132.